PolyPeptide
Coverage of PolyPeptide in the Nexus archive.
- Samsung Biologics buys Swiss peptide maker for $1.8bn
Samsung Biologics has acquired a Swiss peptide manufacturer for $1.8 billion. This acquisition exemplifies South Korean companies expanding abroad through acquisitions.
- Samsung Biologics to acquire Switzerland's PolyPeptide Group in $1.8 billion all-cash deal
Samsung Biologics has acquired PolyPeptide Group in a $1.8 billion all-cash deal. The transaction is valued at 2.7 trillion won.
- PolyPeptide Is Said to Shortlist EQT, IDG for Next Bidding Round
PolyPeptide has shortlisted EQT and IDG for the next bidding round. The move is expected to have significant implications for the companies involved. Further details about the bidding process are not yet available.
- PolyPeptide Studies Strategic Options as Private Equity Circles
PolyPeptide is evaluating strategic options amid private equity interest. The article references a medical laboratory, suggesting potential industry developments. The mention of a photographer indicates visual content related to the story.